A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations.

Subjects

Subjects :

Humans
Patient Selection
Treatment Outcome
Antineoplastic Agents, Immunological adverse effects
Antineoplastic Agents, Immunological therapeutic use
Antineoplastic Combined Chemotherapy Protocols adverse effects
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Carcinoma, Renal Cell drug therapy
Carcinoma, Renal Cell mortality
Carcinoma, Renal Cell pathology
Clinical Decision-Making
Drug Approval
Evidence-Based Medicine standards
Ipilimumab adverse effects
Ipilimumab therapeutic use
Kidney Neoplasms drug therapy
Kidney Neoplasms mortality
Kidney Neoplasms pathology
Nephrology standards
Nivolumab adverse effects
Nivolumab therapeutic use
Urology standards

Details

Language :

English

ISSN :

1873-7560

Volume :

74

Issue :

6

Database :

MEDLINE

Journal :

European urology

Publication Type :

Editorial & Opinion

Accession number :

30201510

Full Text :

https://doi.org/10.1016/j.eururo.2018.08.029